We are live on ! Find out more
PHP

Parkman Healthcare Partners Portfolio holdings

AUM $970M
1-Year Est. Return 79.46%
This Fund
S&P 500
This Quarter Est. Return
-3.4%
1 Year Est. Return
+79.46%
3 Year Est. Return
+312.89%
5 Year Est. Return
+648.59%
10 Year Est. Return
–
AUM
$970M
AUM Growth
-$80.8M
Cap. Flow
+$24.5M
Cap. Flow %
2.53%
Top 10 Hldgs %
34.67%
Holding
117
New
17
Increased
44
Reduced
27
Closed
27

Top Buys

Rank Stock Value
1
LLY icon
Eli Lilly
LLY
+$35.1M
2
PTCT icon
PTC Therapeutics
PTCT
+$19.2M
3
NVST icon
Envista
NVST
+$18.5M
4
SYK icon
Stryker
SYK
+$17.7M
5
ABBV icon
AbbVie
ABBV
+$16.6M

Top Sells

Rank Stock Value
1
MASI
Masimo
MASI
+$26M
2
TERN
Terns Pharmaceuticals
TERN
+$25.1M
3
FOLD
Amicus Therapeutics
FOLD
+$21.2M
4
MCK icon
McKesson
MCK
+$21.1M
5
KNSA icon
Kiniksa Pharmaceuticals
KNSA
+$18M

Sector Composition

Rank Sector Weight
1 Healthcare 99.48%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
SYK icon
1
Stryker
SYK
$127B
$50.9M 5.24%
154,771
+49,299
+47% +$17.7M
DXCM icon
2
DexCom
DXCM
$27.6B
$43.3M 4.47%
689,822
+102,347
+17% +$7.13M
KALV
3
DELISTED
KalVista Pharmaceuticals
KALV
$36.9M 3.81%
1,835,506
+66,998
+4% +$1.08M
PODD icon
4
Insulet
PODD
$11.3B
$32.9M 3.39%
156,561
+15,701
+11% +$3.95M
LLY icon
5
Eli Lilly
LLY
$1.07T
$31.8M 3.28%
+34,616
New +$35.1M
PTCT icon
6
PTC Therapeutics
PTCT
$6.37B
$29.4M 3.03%
431,364
+271,185
+169% +$19.2M
XENE icon
7
Xenon Pharmaceuticals
XENE
$6.32B
$28.9M 2.98%
497,035
+342,851
+222% +$15.8M
BSX icon
8
Boston Scientific
BSX
$65.8B
$28.2M 2.9%
448,768
-51,761
-10% -$4.14M
CVS icon
9
CVS Health
CVS
$137B
$27.8M 2.87%
387,306
-62,906
-14% -$4.85M
RCUS icon
10
Arcus Biosciences
RCUS
$3.57B
$26.1M 2.69%
1,207,274
+238,672
+25% +$5.15M
LIVN icon
11
LivaNova
LIVN
$4.3B
$25.7M 2.65%
403,965
-6,947
-2% -$448K
ZBH icon
12
Zimmer Biomet
ZBH
$17.7B
$24.4M 2.51%
269,557
+118,508
+78% +$10.9M
MBX
13
MBX Biosciences
MBX
$2.95B
$23.9M 2.46%
800,037
-85,602
-10% -$2.91M
ANIP icon
14
ANI Pharmaceuticals
ANIP
$1.77B
$21.6M 2.23%
280,575
+135,575
+94% +$10.6M
SNDX icon
15
Syndax Pharmaceuticals
SNDX
$1.84B
$21.1M 2.17%
901,511
+327,488
+57% +$7.12M
QGEN icon
16
Qiagen
QGEN
$8.53B
$20M 2.06%
500,000
+5,649
+1% +$267K
NVST icon
17
Envista
NVST
$4.28B
$18.1M 1.86%
+711,693
New +$18.5M
EYPT icon
18
EyePoint Inc
EYPT
$1.02B
$17.5M 1.8%
1,354,800
+266,767
+25% +$3.99M
ABBV icon
19
AbbVie
ABBV
$458B
$16.3M 1.68%
+75,000
New +$16.6M
BCRX icon
20
BioCryst Pharmaceuticals
BCRX
$2.37B
$16.3M 1.68%
1,708,099
+808,042
+90% +$6.28M
IQV icon
21
IQVIA
IQV
$34.7B
$14.8M 1.52%
86,702
+51,472
+146% +$10M
AGIO icon
22
Agios Pharmaceuticals
AGIO
$2.16B
$13.7M 1.41%
403,525
+303,921
+305% +$8.62M
ILMN icon
23
Illumina
ILMN
$29.4B
$13.6M 1.4%
+110,370
New +$14.5M
EW icon
24
Edwards Lifesciences
EW
$47.6B
$13.4M 1.38%
167,155
+16,170
+11% +$1.33M
NBIX icon
25
Neurocrine Biosciences
NBIX
$17.7B
$13.1M 1.35%
99,069
-15,643
-14% -$2.08M
1
2 3 4 5

Similar funds

LOIM
Liberty One Investment Management Libertyville, Illinois $970M AUM 12.15% 1-Year Est. Return
CFP
Cascade Financial Partners San Diego, California $970M AUM 19.9% 1-Year Est. Return
SFO
Stokes Family Office New Orleans, Louisiana $969M AUM 19.6% 1-Year Est. Return
MGCM
Mane Global Capital Management New York $971M AUM 58.5% 1-Year Est. Return
PWPS
Pinnacle Wealth Planning Services Mansfield, Ohio $968M AUM 19.1% 1-Year Est. Return
JWM
Jackson Wealth Management Lake Mary, Florida $972M AUM 22.58% 1-Year Est. Return
WAM
WNY Asset Management Williamsville, New York $967M AUM
GLR
Great Lakes Retirement Sandusky, Ohio $967M AUM 25.11% 1-Year Est. Return

Parkman Healthcare Partners's Q1 2026 Portfolio in Review

As of Q1 2026, Parkman Healthcare Partners held 117 positions worth $970M, down 7.7% from $1.05B the previous quarter. Its ten largest holdings account for 35% of the portfolio.

Parkman Healthcare Partners's Q1 2026 filing shows 17 new, 44 increased, 27 reduced and 27 closed positions. Its largest new stake was Eli Lilly: 34,616 shares worth $31.8M. The largest sale was Masimo, an estimated $26M.

By sector, the portfolio is most concentrated in Healthcare at 99% of assets, down from 100% a quarter earlier.

  • Parkman Healthcare Partners's largest Q1 2026 buy was Eli Lilly: 34,616 shares worth $31.8M.
  • Parkman Healthcare Partners added most to PTC Therapeutics in Q1 2026, an estimated $19.2M increase.
  • Parkman Healthcare Partners's biggest Q1 2026 reduction was McKesson, cutting an estimated $21.1M.
  • Parkman Healthcare Partners fully exited Masimo in Q1 2026, selling an estimated $26M.
  • Parkman Healthcare Partners's ten largest holdings make up 35% of its $970M portfolio in Q1 2026.
  • Parkman Healthcare Partners opened 17 new positions and closed 27 in Q1 2026.
  • Parkman Healthcare Partners's portfolio value fell 7.7% quarter-over-quarter to $970M.

Based on Parkman Healthcare Partners's 13F filing for Q1 2026, filed 15 May 2026.